Myelodysplastic/myeloproliferative neoplasms.

@article{Cazzola2011MyelodysplasticmyeloproliferativeN,
  title={Myelodysplastic/myeloproliferative neoplasms.},
  author={Mario Cazzola and Luca Malcovati and Rosangela Invernizzi},
  journal={Hematology. American Society of Hematology. Education Program},
  year={2011},
  volume={2011},
  pages={
          264-72
        }
}
According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myelodysplastic/myeloproliferative neoplasms are clonal myeloid neoplasms that have some clinical, laboratory, or morphologic findings that support a diagnosis of myelodysplastic syndrome, and other findings that are more consistent with myeloproliferative neoplasms. These disorders include chronic myelomonocytic leukemia, atypical chronic myeloid leukemia (BCR-ABL1 negative… Expand
Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid malignancies that are characterized by dysplasia resulting in cytopenias as well as proliferative features such asExpand
Peculiarities in the Diagnosis Approach of MDS /MPN-U Patients.
TLDR
Two cases are described in this article: one diagnosed with RARS-T and one with MDS / MPN-U, both cases evolved towards acute myeloid leukemia. Expand
Chronic myelomonocytic leukemia: Forefront of the field in 2015.
TLDR
This work discusses the latest molecular characterization of the disease, including how molecular factors affect current prognostic models and available treatment strategies, with a special emphasis on experimental and forthcoming therapies. Expand
Chapter 9 Role of Cytogenetic Analysis in the Diagnosis and Classification of Hematopoietic Neoplasms
The malignant cells in many patients who have leukemia, lymphoma, or another hematologic neoplasm have acquired clonal chromosomal abnormalities. Specific cytogenetic abnormalities are closely, andExpand
Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable
  • K. Zoi, N. Cross
  • Biology, Medicine
  • International Journal of Hematology
  • 2014
TLDR
The various combinations of mutations indicate a multi-step pathogenesis, which likely contributes to the marked clinical heterogeneity of these disorders and the delineation of complex clonal architectures may serve as the cornerstone for the identification of novel therapeutic targets and lead to better patient outcomes. Expand
Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
TLDR
The results suggest that incorporation of JAK2 mutation testing and karyotyping allows for monitoring of disease progression with prognostic and therapeutic implications in Philadelphia chromosome-negative myeloproliferative neoplasms. Expand
Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.
TLDR
It is demonstrated that combining blood routine parameters and the morphological analysis of peripheral blood cells have an essential role in the reliable diagnosis of MDS/MPN based on WHO categories. Expand
Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review
TLDR
A 58-year-old man with splenomegaly, hyperleukocytosis, anemia, and thrombocytopenia is admitted and the diagnosis of aCML was made according to 2016 World Health Organization diagnostic criteria. Expand
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
TLDR
It is found that SF3B1 mutations are independent predictors of favorable clinical outcome, and their incorporation into stratification systems might improve risk assessment in MDS. Expand
Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications
TLDR
The basic molecular aberrations in MDS/MPN overlap syndromes and their possible future implications are reviewed. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 60 REFERENCES
The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features
TLDR
The current ‘spotlight’ review provides practical guidelines, which should allow for a reproducible classification of these uncommon neoplasms when encountered in clinical practice, and is being replaced by ‘MDS/MPN’ that will be used in this review. Expand
Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
  • M. Loh
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2010
TLDR
The spectrum of mutations described thus far in JMML occur in genes that encode proteins that signal through the Ras/mitogen-activated protein kinase (MAPK) pathways, thus providing potential new opportunities for both diagnosis and therapy. Expand
World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
  • J. Vardiman, E. Hyjek
  • Biology, Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2011
TLDR
An understanding of the clinical, morphologic, and genetic features of the MPN variants will facilitate their diagnosis and, in most cases, correlation of clinical, genetic, and morphologic findings is required for diagnosis and classification. Expand
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
TLDR
The current status of pharmacotherapy and transplantation in chronic myelomonocytic leukaemia is summarized and recent results of molecular research for diagnosis of this heterogeneous entity are outlined. Expand
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
TLDR
Researchers could not confer objective evidence suggesting that arbitrary divisions of CMML by white blood cell counts into "dysplastic" and "proliferative" categories reflect clinical entities differing in the risk of acute leukemia development, although a trend of shorter survival in patients with leukocytosis was observed. Expand
Cytogenetic risk stratification in chronic myelomonocytic leukemia
TLDR
Cytogenetic findings have a strong prognostic impact in patients with chronic myelomonocytic leukemia and were confirmed as an independent prognostic variable for overall survival on univariate and multivariate analysis. Expand
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
TLDR
The decitabine adverse event profile seen in CMML patients was similar to observations in other hematologic patient populations, with myelosuppression and related infectious complications, and suggest that studies in other myeloproliferative diseases may be warranted. Expand
PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms
TLDR
JAK2 is a tyrosine kinase with oncogenic potential in hematologic malignancies that can be activated by point mutations, translocations and amplifications, which merits prospective evaluation of specific drugs blocking JAK2. Expand
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts
TLDR
The proposals of the IWGM-MDS for the definition of myeloblasts, promyelocytes and ring side-roblasts in patients with myelodysplastic syndrome are detailed. Expand
Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts
TLDR
A mutation analysis of TET2 in patients with myeloid neoplasms associated with ring sideroblasts indicates the existence of a single dominant clone with multiple mutations, consistent with the initial emergence of a clone of hematopoietic cells carrying a single mutation of Tet2 and the subsequent development of subclones that carry additional TET1 mutations and become dominant with time. Expand
...
1
2
3
4
5
...